Genomics Bioscience & Technology Co EBIT per Share
The EBIT per Share of Genomics Bioscience & Technology Co (4195.TWO) as of Oct 9, 2026 is -1.03 TWD. In the previous year, EBIT per Share was -3.15 TWD — a change of -67.32% (higher).
Get this data via API
Financial Data API
EBIT per Share
-1.03TWD
YoY
-67.32%
Last updated:
The Genomics Bioscience & Technology Co EBIT per Share history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT per Share | YoY |
|---|---|---|
| -1.03TWD | -67.32% | |
| -3.15TWD | +40.85% | |
| -2.24TWD | -289.62% | |
| 1.18TWD | +548.38% | |
| 0.18TWD | +575.27% | |
| 0.03TWD | -77.00% | |
| 0.12TWD | -117.49% | |
| -0.67TWD | +0.31% | |
| -0.67TWD | -15.88% | |
| -0.79TWD | +27.57% | |
| -0.62TWD | -17.39% | |
| -0.75TWD | -48.51% | |
| -1.46TWD | -45.66% | |
| -2.69TWD | -640.04% | |
| 0.50TWD | -117.25% | |
| -2.89TWD | — |
Genomics Bioscience & Technology Co Stock analysis
Frequently Asked Questions about Genomics Bioscience & Technology Co stock
EBIT per Share of Genomics Bioscience & Technology Co is -1.03 TWD in 2025.
EBIT per Share of Genomics Bioscience & Technology Co changed from -3.15 TWD to -1.03 TWD, representing a -67.32% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Genomics Bioscience & Technology Co since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Income Statement — Genomics Bioscience & Technology Co
All Key Metrics — Genomics Bioscience & Technology Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth